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The use of bacteriophages to combat bacterial infections may help to 
address the current crisis of antibiotic resistance. Fundamental issues 
arising from the ecological dynamic of host, bacterium and phage can be 
investigated in trees, offering both a natural approach to treating plant 
disease, and a chance to avoid creating a new resistance problem.  
Michael Gross reports. 
Phage therapies for plants and people Leaf life: Prints of sycamore, alder, ash and 
oak leaves stamped on nutrient agar plates 
and incubated overnight to visualise the 
microbial communities on the leaf surface. 
(Photo: © Britt Koskella, University of Exeter.)Antibiotics have saved millions of 
lives in the past seven decades, 
but their future usefulness is now 
severely threatened by the spread  
of resistance genes and the 
shortage of new substances that 
can overcome resistance (Curr. Biol. 
(2013) 23, R1063–R1065). Several 
recent reports, including one from 
the WHO released in April, have 
confirmed that this problem is 
now on the verge of turning into a 
humanitarian disaster on a global 
scale.
Due to the imminent danger, the 
search for alternatives to traditional 
antibiotics has become an urgent 
priority. One promising avenue is 
the use of natural bacteriophages 
in mixtures known as phage 
cocktails. Originally proposed by the 
discoverer of phages, Felix d’Herelle, 
the idea was pursued in the Soviet 
Union (especially in Tbilisi, Georgia) 
and Poland, but largely ignored in 
the Western world, as antibiotics 
were considered superior (Curr. Biol. 
(2011) 21, R267–R270). 
Now, however, researchers in 
Germany, France, and Belgium, 
among other countries, are busy 
identifying phages for therapeutic 
human uses. The Food and Drugs 
Administration (FDA) in the US 
has already approved the use of 
phages in the treatment of food 
products, specifically raw meat. 
Trials of phages as biopesticides in 
agriculture have also been reported 
for a number of crops, including 
tomato, potato, citrus fruit and 
onion. 
If phages are going to replace  
all or some of the current 
applications of antibiotics spanning 
not only medicine but also 
agriculture and aquaculture, will we 
just repeat the mistake we made 
with antibiotics and breed phage-
resistant strains? The outcome is more difficult to predict than in the 
case of antibiotics, as the phages 
co-evolve with their host bacteria as 
well as the eukaryotic host infected 
by those bacteria, so there is an 
ecological triangle that needs to be 
understood. 
Ecological triangulation
Much of the recent research on 
the ecology of phages infecting 
disease-causing bacteria has been 
done on plants. Therefore, the use 
of phages to treat plant disease is 
already becoming a very real option. 
At a recent one-day, NERC-funded 
symposium hosted by the group of 
Rob Jackson at the University of 
Reading, botanists and ecologists 
from several institutions pondered 
the possibility of phage therapy for 
trees. 
Britt Koskella from the University 
of Exeter discussed the issue on the 
basis of research carried out with 
her PhD student Sean Meaden into 
the co-evolution of phages with their 
hosts. 
On a very practical level,  
Koskella addressed the question 
of how to select phages for 
applications and how to assess  
their specificity.  “Based on what  
we know from our tree research, 
phages are out there already and 
they are well-adapted to their  
local bacteria including those 
pathogens causing important tree 
diseases. Therefore, in designing 
treatments it makes good sense 
to first look at which phages are 
successful in nature and why,” 
Koskella said. 
As far as tests for specificity  
are concerned, traditional laboratory 
assays based on a small selection of 
cultured strains may not be sufficient 
to rule out unexpected side effects. 
Instead, Koskella argued, the tests 
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Phage healing: Studies on horse chestnut trees show how phages can limit the spread of 
bacterial infection. (Photo: © Sarah James, University of Reading.)should be based on the diversity of 
species that the phages are likely to 
encounter in the field. 
Phages are typically applied 
as a cocktail of several variants, 
both in order to cover different 
strains of the target species and 
to make it less likely that they 
evolve resistance, as they often 
do in the wild. Should resistance 
be observed, however, this does 
not automatically mean the failure 
of the treatment. As resistance to 
specific kinds of phages can come 
at a relatively high fitness cost to 
the host, bacteria will only keep the 
resistance traits that are useful in 
an acute threat situation. Switching 
the phage treatment on a bacterial 
population can therefore overcome 
its resistance.  
“We are now looking into the 
possibility of creating unique 
combinations of phages that force 
the bacteria to evolve particularly 
costly resistance. This means that 
resistance is more likely to be lost 
once the treatment has stopped, and 
is less likely to spread to other hosts,” 
Koskella said.  
This kind of response may also help 
to avoid a repetition of the antibiotics 
crisis in phages. As Meaden and 
Koskella have explained in a recent 
review (Frontiers in Microbiology 
(2013) 4, 358), a rapid response in switching regimes will help to 
keep resistance at bay. For this to 
be practically feasible in medical 
applications of phages, protocols 
have to be found for the production of 
phage cocktails that are considered 
safe in human application, such that 
new cocktails can be introduced 
without the delay of new medical 
trials. 
Beyond the resistance problem, 
which is broadly analogous to the 
one we already have with antibiotics, 
there are a few additional problems 
and questions arising from the 
specific properties of phages 
and their ability to propagate and 
evolve. For one, the fact that the 
production of phages generally 
requires the use of their bacterial 
host, a phage therapy for a highly 
dangerous bacterium might have 
to be produced in high-security 
laboratories with all the difficulties 
attached to this.
Furthermore, as Meaden and 
Koskella explain in their review, 
the presence of phages tends to 
facilitate horizontal gene transfer 
between bacteria, which in turn may 
further the spread of undesirable 
genetic traits including virulence 
traits and resistance to antibiotics. 
To avoid exaggerated fears, 
however, it is important to make 
the distinction between lytic and temperate phages. Lytic phages can 
only propagate by killing their hosts, 
and they are the kind that one would 
consider using as antimicrobial 
agents. Temperate phages can 
lead a more peaceful coexistence 
with their hosts and sometimes 
carry virulence factors that make 
their hosts more dangerous, the 
most prominent example being 
the cholera toxin. These would 
obviously not be considered for 
phage therapy. 
Further phage-specific ecological 
complications that Koskella 
and Meaden have highlighted in 
their review include the impact 
that phages can have on natural 
ecosystems, including, in medical 
applications, the gut microbiome,  
as well as the intrinsic 
unpredictability of the doses of 
phages that will be present after  
they are released. This type of 
ecological question, Koskella 
emphasizes, is easier to address in 
tree hosts than in human patients, 
but the results should be broadly 
applicable.
Nevertheless, the authors conclude 
that, with improving ecological 
understanding and with the modern 
analytical tools allowing the  
monitoring of phage populations  
after their release, the application 
of phages in the environment and 
in medical practice can be handled 
responsibly and may provide a 
solution for the current antibiotics 
crisis. 
Treating tree disease
The laboratory of Rob Jackson at 
Reading, which hosted the recent 
meeting on phage therapy for trees, 
started a collaborative study into  
the possibility of using phages 
to treat bleeding canker disease 
in horse chestnut trees in 2010, 
together with Michael Brockhurst 
at York and the company Bartletts 
Tree Experts. The research, mostly 
conducted by Sarah James at 
Reading in the course of her PhD 
thesis, identified a number of phage 
strains that can infect the bleeding 
canker pathogen Pseudomonas 
syringae pv. aesculi.  
Horse chestnut mainly serves 
for decorative purposes in parks in 
the UK and has no major economic 
importance, but, given the ecological 
research conducted by Koskella 
and others on this system, it offers 
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Aquaculture: Shrimp farming in South East Asia is notorious for its unsustainable use of 
antibiotics in the water. This is another area where the use of phages may be beneficial. 
(Photo: NOAA/Wikimedia Commons.)a well-defined model for phage 
therapy in trees. In contrast to  
the earlier work from Koskella  
and other ecologists, Jackson’s 
team not only observed and  
used natural phages, but also 
manipulated the phage strains in 
the laboratory, breeding them to 
optimise their ability to infect the 
plant pathogen. 
The researchers are aiming to 
blend some of these derived, more 
infectious strains together with 
the wild type found in the natural 
environment, in order to kill off the 
pathogens more effectively. Having 
optimised their phage cocktails, 
the researchers have now reached 
the stage of early application trials, 
attempting to cure infected trees.  
“Tantalisingly, our preliminary tests 
show promise as the application 
of a two-phage cocktail helped 
to reduce disease symptoms and 
pathogen numbers in infection 
sites in the trunk of horse chestnut 
saplings. However, this needs to be 
repeated in more trees of different 
size and ages,” Jackson explains. 
“Moreover, another critical question 
emerges — does the co-evolution 
(breeding) seen in vitro occur in 
the plant and can it occur with 
phage cocktails? This needs to be 
addressed to determine if, over time, 
phage use would become redundant 
much the same as the use of some 
antibiotics.”
To rule out such unwanted 
results, Jackson says, phage strains 
intended for applications — even if 
used in cocktails — must be tested 
individually for their evolutionary 
dynamic in the ecological context. 
“We must also examine the molecular 
changes occurring to determine 
if there is any likely end-point in 
bacterial resistance — will, using 
enough phages in a cocktail, 
bacteria be prevented from evolving 
resistance? This helps with risk 
assessment — to predict the 
likelihood of resistance emerging,” 
Jackson concludes. 
Meanwhile, a different strain  
of the bleeding canker bacterium, 
Pseudomonas syringae pv. 
actinidiae, is devastating kiwi 
plantations in New Zealand, 
threatening to cause significant 
economic damage to the country. 
The group of Peter Fineran at the 
University of Otago has recently 
published an investigation of  more than 200 phages that show 
activity against this pathogen,  
laying the foundation for the  
design of a phage cocktail to deal 
with this problem (Appl. Environ. 
Microbiol. (2014) http://dx.doi.
org/10.1128/AEM.00062-14).
Further potential for the 
application of phages lies in 
aquaculture, such as shrimp farming, 
where the current approach to 
fighting bacterial disease is an 
unsustainable release of antibiotics 
into the water. 
Treating human disease 
A number of research projects are 
already underway to develop well-
defined phage therapies for specific 
clinical applications. For instance, 
the European Commission’s seventh 
Framework programme supports an 
international collaboration called 
Phagoburn (http://www.phagoburn.
eu/), aiming to develop treatments 
for burn wounds infected with 
Escherichia coli and Pseudomonas 
aeruginosa.  
One of the urgent problems 
connected to the rapid spread 
of antibiotics resistance is the 
occurrence in hospitals of multi-
drug resistant Staphylococcus aureus, widely known as MRSA — or 
“hospital superbug” in the popular 
media. The group of Robert Lavigne 
at the University of Leuven, Belgium, 
has recently identified a pair of new 
phage strains dubbed Romulus 
and Remus, which represent a new 
species within the known genus 
of Twortlikevirus (J. Virol. (2013), 
87, 3237–3247). Detailed molecular 
analysis of how these phages 
interact with their hosts suggests 
that they might be suitable for phage 
therapy of MRSA infections, as 
they can dissolve biofilms, which 
are a particularly tricky problem 
in the application of antibiotics in 
infections. 
Iyo Takemura-Uchiyama and 
colleagues at Kochi University, 
Japan, have also described new 
phages active against MRSA (FEMS 
Microbiol. Lett. (2013) 347, 52–60). 
They tested its therapeutic efficiency 
in a new setup using silkworm 
larvae, which they advocate as 
a cost-efficient way of replacing 
animal tests with rodents (Nature 
(2014) 509, S9).  
The company Novolytics, based 
in Chorley, Lancashire, UK, is also 
in the process of developing phage 
therapies against MRSA. At the 
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recycling nutrients that previously 
were entrapped in the sedimentary 
column, deeper burrowing may have 
been crucial to igniting the evolutionary 
‘explosion’ in the Cambrian during 
which a host of new body plans 
appeared; and it was surprising just 
how quickly thereafter a wide range 
of foraging and grazing habits were 
innovated on the Phanerozoic seafloor.
Seilacher recognised that it is not 
absolutely necessary to know exactly 
what kind of organism was at work 
on a track or trail to understand 
the exploitation of the seafloor. 
Which animal left a trace is often 
impossible to determine, as body 
fossils are rarely preserved in the 
same paleoenvironments as trace 
fossils. However, the bigger picture 
of environmental exploitation was 
accessible to analysis, as analogous 
foraging techniques had evolved 
repeatedly through geological time. 
Seilacher was incomparable when it 
came to ‘reading’ traces as biological 
activity. But he was equally convinced 
that some very particular ‘species’ of 
ichnofossils could be used to date 
rocks in areas where body fossils were 
lacking. This was applied with success 
to correlate Palaeozoic rocks over huge 
areas of North Africa that had previously 
defied geological classification. 
Although much of his groundwork on 
ichnology was done in the twentieth 
century, Seilacher finally summarised 
his lifetime’s interest in the book Trace 
Fossil Analysis published in 2007 when 
he was over eighty.
It was a logical extension of his 
ichnological work — and also a 
long-standing interest in special 
fossil preservations, which he termed 
Konservat Lagerstätten in 1970 
— that propelled Seilacher to study 
the curious Precambrian fossils of the 
Ediacaran rocks of South Australia 
and elsewhere. These large — and 
largely mysterious — organisms 
were the only substantial metazoans 
preceding the Cambrian appearance 
of our familiar animal phyla, and they 
are preserved in the kind of sandstones 
and shales with which Seilacher was 
so familiar. They comprise a very wide 
range of morphologies, and some had 
previously been interpreted in relation 
to younger metazoans, as ‘missing 
links.’ Characteristically, Seilacher 
at once came back with a radically 
dissenting interpretation: these were 
quilted organisms of a kind radically 




For decades the tall and commanding 
presence of Dolf Seilacher at 
paleontology conferences was 
something that was both welcomed 
and dreaded by younger colleagues: 
welcomed because it was flattering 
having the invariably rapt attention 
of one of the few globally recognised 
scientists in the field; dreaded because 
that attention often transmuted 
into a penetrating question coming 
from a direction nobody could have 
anticipated. Seilacher was one of the 
great lateral thinkers. He belonged 
neither to the earth nor to the life 
sciences, but made fundamental, 
synergistic contributions to both. This 
was finally recognised by the award of 
the Crafoord Prize in 1992.
Most paleontologists study fossils in 
the privacy of their own laboratories. 
The ideal fossil might be cleaned of 
its sedimentary matrix the better to 
get down to the details. Dolf Seilacher 
was as interested in the relationships 
of fossils to the enclosing rock as he 
was in any bone or shell. During the 
1960s and 1970s he was seminal in the 
development of the study of the tracks 
and trails left by biological activity on 
the surface or within sediments — 
those destined to become trace fossils, 
or ‘ichnofossils’ as they are known. He 
discriminated various ways in which 
such tracks could be impressed upon 
or cast by clays and sands, so that 
a previous, rather naïve view based 
essentially on the image of a footfall 
upon a beach became much more 
nuanced. Even the most delicate and 
momentary behavioural maneuvers 
within the sediment could leave an 
eternal imprint if the conditions for 
their preservation were just right. 
Recognition of different types of 
locomotion and foraging activities then 
became integrated with geological field 
studies around the world that proved 
that there were distinct suites of 
ichnofossils typifying different ancient 
marine depth-zones and habitats. The 
broad evolutionary sweep of trophic 
history thus became a subject for 
rational observation: for example, by 
ObituaryReading meeting, John Hardcastle from the company discussed 
the commercial and regulatory 
challenges attached to such 
endeavours.
Christine Rohde and Johannes 
Wittmann at the German Collection of 
Microorganisms and Cell Cultures in 
Braunschweig are in the process of 
expanding their arsenal of medically 
useful phage strains. Most recently, 
they reported the characterisation 
of phages against the opportunistic 
bacterial pathogen Achromobacter 
xylosoxidans, which causes 
complications in patients with cystic 
fibrosis and often carries multiple 
antibiotic resistance traits (PLoS One 
(2014) 9, e86935; Virology Journal 
(2014) 11, 14).
While research aimed at medical 
application of phages is making 
rapid progress, a key problem 
remains the mismatch between 
the biological properties of phages 
and the established regulatory 
frameworks for drugs and medical 
procedures. As mentioned above, 
the success of phage therapy may 
depend on rapid change to the 
recipe, outrunning the evolution of 
the targeted bacteria. This need 
for change and for efficient use of 
the natural diversity of phages runs 
against the grain of the established 
drug regulations and guidelines 
which aim to pin down the precise 
and unchangeable composition of a 
given treatment and require time-
intensive testing of this very specific 
product. 
Therefore, Gilbert Verbeken and 
colleagues at Leuven and Brussels 
have argued that adaptation of 
existing drug rules for phages  
would be impractical (Arch. Immunol. 
Ther. Exp. (2014) 62, 117–129). The 
authors call on the European Union 
to set up new guidelines specifically 
for phage therapy, based on the 
ecological knowledge accumulated 
in recent years. The important 
message to regulators as well as 
to future users of phage therapies 
is that, even though they may one 
day replace antibiotics, they don’t 
behave like antibiotics, and we, as a 
civilisation, definitely don’t want to 
repeat the mistakes we made with 
antibiotics. 
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